Data Sheet

Product Name:	(E)-Necrosulfonamide
Cat. No.:	CS-5851
CAS No.:	1360614-48-7
Molecular Formula:	C18H15N5O6S2
Molecular Weight:	461.47
Target:	Mixed Lineage Kinase
Pathway:	MAPK/ERK Pathway
Solubility:	DMSO : ≥ 28 mg/mL (60.68 mM); H2O : < 0.1 mg/mL (insoluble)



BIOLOGICAL ACTIVITY:

(E)-Necrosulfonamide is a **necroptosis** inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein **(MLKL)** to block the necrosome formation. **In Vitro:** (E)-Necrosulfonamide (0.5-2.5 μM; 20 hours) reduced TRAIL (50 ng/mL) and STS (1 μM) -induced necroptosis in a concentration-dependent manner[3].

References:

[1]. Steinhart L et al. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells andovercome apoptosis resistance by inducing necroptosis. Cell Death Dis. 2013 Sep 12;

[2]. Sun L et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012 Jan 20;148(1-2):213-27.

[3]. Dunai ZA et al. Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One. 2012;7(7):

[4]. Bae JH et al. Chemical regulation of signaling pathways to programmed necrosis. Arch Pharm Res. 2014 Jun;37(6):689-97.

CAIndexNames:

2-Propenamide, N-[4-[[(3-methoxy-2-pyrazinyl)amino]sulfonyl]phenyl]-3-(5-nitro-2-thienyl)-, (2E)-

SMILES:

O=C(NC1=CC=C(S(=O)(NC2=NC=CN=C2OC)=O)C=C1)/C=C/C3=CC=C([N+]([O-])=O)S3.[(E)]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA